ProfessorSalman Siddiqui
Clinical Chair of Respiratory Medicine
National Heart & Lung Institute - Faculty of Medicine
Orcid identifier0000-0003-3770-7870 (opens in a new tab)
- Clinical Chair of Respiratory MedicineNational Heart & Lung Institute - Faculty of Medicine
- 020 7594 5303 (Work)
- St Mary's Research Building, St Mary's Campus, United Kingdom
BIO
Professor Salman Siddiqui is a Clinical professor of Respiratory and Experimental Medicine at Imperial College.
Professor Siddiqui is also an honorary NHS consultant at Imperial Healthcare Trust, with specialist expertise in severe asthma and eosinophilic lung disease (in particular EGPA).
Key roles
NIHR Imperial BRC- Respiratory Co-theme lead
NIHR-TRC, National Asthma Research Strategy Group Lead
European Respiratory Society - Clinical Research Collaborations Director
Research Interests
Experimental Medicine
Professor Siddiqui is leading and has led several clinical trials programs targeting type-2 immune dysfunction in severe asthma and EGPA. These have led to the first novel oral highly potent anti-eosinophil compound to progress to pivotal phase three trials in moderate-severe asthma [PMID:37277072] which he co-leads. Professor Siddiqui is also directing an investigator initiated an anti-alarmin experimental medicine trials program across the UK, targeting TSLP in EGPA to understand the role of ILC2 cells in EGPA pathogenesis and also the impact of alarmin directed therapies in this rare immune mediated vasculitis. This latter trial is supported by the Imperial Clinical Trials Unit and the Imperial Vasculitis Centre. Professor Siddiqui is interested in the role of eosinophils in airway tissue remodelling in severe asthma [PMID:37343842], in this context in collaboration with Professor Clare Lloyd, he is examining the role of highly multiplexed tissue platforms: imaging mass cytometry, spatial transcriptomics and REIMS metabolic imaging - to determine the impact of eosinophil depletion on tissue remodelling and type-2 immune dysfunction in severe asthma.
Digital Lung Twins Research
Professor Siddiqui pioneered the development of tools in asthma to study the small airways in clinical practice. In the early stages of his career through efforts in the EU-FP7 AirPROM consortium he validated the use of the forced oscillation technique to study the small airways using whole organ physiomic patient specific computational airway models and imaging biomarkers (digital twins of the lung) integrating physics based simulations of lung physiology [PMID:31106566 & 30682455].
These efforts led to the development of the multi-national ATLANTIS program, which he co-led and identified that (I) oscillometry is a reliable measure of small airways disease in asthma using biostatistical models [PMID:30876830], (II) that oscillometry is associated with asthma outcomes longitudinally [PMID:35247313] and (III) ultimately led to the development and validation of a simple diagnostic questionnaire for small airways disease for potential early disease screening in primary care [PMID:36517179].
Professor Siddiqui, has recently been awarded funding from Asthma UK/BLF partnership to study the role of a novel low cost triple diagnostic device including oscillometry, as a simple asthma diagnostic in North West London in conjunction with diagnostic hubs and continues to develop the digital twin models from AirPROM in a new EPSRC Network Plus program focussed on biophysical lung models that he co-leads called BIOREME (https://www.bioreme.net/about), which will look to develop multi-scale lung models from cell-tissue-organ in diseases such as asthma.
Human Volatilomics
In previous work whilst at the University of Leicester, Professor Siddiqui coordinated (Co-Founder, Chief Investigator and Co-I), an EPSRC/MRC funded pathology node. The pathology node comprised of a partnership between the NHS trust, BRC, CRF, University and Academic Health Science Network, together with several industry partners (pharma and sensors/analytical chemistry focussed). Several developmental and subsequently high impact publications have followed (PMID:36383685), alongside several exclusive breath signature patents (WO2023002167A2) for which Professor Siddiqui is a co-inventor with further patents pending as primary inventor focussing on eosinophil derived VOCs.
Following his appointment at NHLI-Imperial, Professor Siddiqui has been awarded MRC Capital funding to establish the world’s first Cyclic-IMS ambient volatilomics program (breath and tissue headspace) with a cross facultyImperial partnership (Professor Zoltan Takats) as well as several external partners including the Oxford Rosalind Franklin Institute, Universities of Liege and Leicester (Professor Paul Monks) and ion mobility SME Imspex diagnostic. This dedicated respiratory phenomics lab at the Sir Michael Uren Campus (White City) will also host GC-MS, automated thermal desorption tube sampling for large scale analysis capability and portable (for in clinic use) Ion Mobility sensors. Ongoing development work is exploring the potential of synthetic olfactory nano-sensor arrays with Professor's Klug and Ces (Faculty of Natural Sciences).
Professor Siddiqui is also an honorary NHS consultant at Imperial Healthcare Trust, with specialist expertise in severe asthma and eosinophilic lung disease (in particular EGPA).
Key roles
NIHR Imperial BRC- Respiratory Co-theme lead
NIHR-TRC, National Asthma Research Strategy Group Lead
European Respiratory Society - Clinical Research Collaborations Director
Research Interests
Experimental Medicine
Professor Siddiqui is leading and has led several clinical trials programs targeting type-2 immune dysfunction in severe asthma and EGPA. These have led to the first novel oral highly potent anti-eosinophil compound to progress to pivotal phase three trials in moderate-severe asthma [PMID:37277072] which he co-leads. Professor Siddiqui is also directing an investigator initiated an anti-alarmin experimental medicine trials program across the UK, targeting TSLP in EGPA to understand the role of ILC2 cells in EGPA pathogenesis and also the impact of alarmin directed therapies in this rare immune mediated vasculitis. This latter trial is supported by the Imperial Clinical Trials Unit and the Imperial Vasculitis Centre. Professor Siddiqui is interested in the role of eosinophils in airway tissue remodelling in severe asthma [PMID:37343842], in this context in collaboration with Professor Clare Lloyd, he is examining the role of highly multiplexed tissue platforms: imaging mass cytometry, spatial transcriptomics and REIMS metabolic imaging - to determine the impact of eosinophil depletion on tissue remodelling and type-2 immune dysfunction in severe asthma.
Digital Lung Twins Research
Professor Siddiqui pioneered the development of tools in asthma to study the small airways in clinical practice. In the early stages of his career through efforts in the EU-FP7 AirPROM consortium he validated the use of the forced oscillation technique to study the small airways using whole organ physiomic patient specific computational airway models and imaging biomarkers (digital twins of the lung) integrating physics based simulations of lung physiology [PMID:31106566 & 30682455].
These efforts led to the development of the multi-national ATLANTIS program, which he co-led and identified that (I) oscillometry is a reliable measure of small airways disease in asthma using biostatistical models [PMID:30876830], (II) that oscillometry is associated with asthma outcomes longitudinally [PMID:35247313] and (III) ultimately led to the development and validation of a simple diagnostic questionnaire for small airways disease for potential early disease screening in primary care [PMID:36517179].
Professor Siddiqui, has recently been awarded funding from Asthma UK/BLF partnership to study the role of a novel low cost triple diagnostic device including oscillometry, as a simple asthma diagnostic in North West London in conjunction with diagnostic hubs and continues to develop the digital twin models from AirPROM in a new EPSRC Network Plus program focussed on biophysical lung models that he co-leads called BIOREME (https://www.bioreme.net/about), which will look to develop multi-scale lung models from cell-tissue-organ in diseases such as asthma.
Human Volatilomics
In previous work whilst at the University of Leicester, Professor Siddiqui coordinated (Co-Founder, Chief Investigator and Co-I), an EPSRC/MRC funded pathology node. The pathology node comprised of a partnership between the NHS trust, BRC, CRF, University and Academic Health Science Network, together with several industry partners (pharma and sensors/analytical chemistry focussed). Several developmental and subsequently high impact publications have followed (PMID:36383685), alongside several exclusive breath signature patents (WO2023002167A2) for which Professor Siddiqui is a co-inventor with further patents pending as primary inventor focussing on eosinophil derived VOCs.
Following his appointment at NHLI-Imperial, Professor Siddiqui has been awarded MRC Capital funding to establish the world’s first Cyclic-IMS ambient volatilomics program (breath and tissue headspace) with a cross facultyImperial partnership (Professor Zoltan Takats) as well as several external partners including the Oxford Rosalind Franklin Institute, Universities of Liege and Leicester (Professor Paul Monks) and ion mobility SME Imspex diagnostic. This dedicated respiratory phenomics lab at the Sir Michael Uren Campus (White City) will also host GC-MS, automated thermal desorption tube sampling for large scale analysis capability and portable (for in clinic use) Ion Mobility sensors. Ongoing development work is exploring the potential of synthetic olfactory nano-sensor arrays with Professor's Klug and Ces (Faculty of Natural Sciences).
FACULTY
- Faculty of Medicine
POSITION NAME
- Clinical Chair of Respiratory Medicine